Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.79 Billion KRW | -43.02% |
| 2022 | 32.98 Billion KRW | 8.28% |
| 2021 | 30.46 Billion KRW | 141.01% |
| 2020 | 12.63 Billion KRW | 7.6% |
| 2019 | 11.74 Billion KRW | 1.03% |
| 2018 | 11.62 Billion KRW | 49.86% |
| 2017 | 7.75 Billion KRW | 5.44% |
| 2016 | 7.35 Billion KRW | -31.59% |
| 2015 | 10.75 Billion KRW | -30.34% |
| 2014 | 15.44 Billion KRW | -8.88% |
| 2013 | 16.94 Billion KRW | -51.36% |
| 2012 | 34.84 Billion KRW | 90.07% |
| 2011 | 18.33 Billion KRW | -2.85% |
| 2010 | 18.87 Billion KRW | 94.94% |
| 2009 | 9.68 Billion KRW | -1.01% |
| 2008 | 9.77 Billion KRW | -72.98% |
| 2007 | 36.19 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.45 Billion KRW | -39.21% |
| 2024 Q1 | 13.91 Billion KRW | -25.96% |
| 2023 Q1 | 33.47 Billion KRW | 1.48% |
| 2023 Q4 | 18.79 Billion KRW | -4.43% |
| 2023 FY | 18.79 Billion KRW | -43.02% |
| 2023 Q2 | 29.87 Billion KRW | -10.74% |
| 2023 Q3 | 19.66 Billion KRW | -34.18% |
| 2022 Q2 | 28.99 Billion KRW | 0.31% |
| 2022 FY | 32.98 Billion KRW | 8.28% |
| 2022 Q4 | 32.98 Billion KRW | 7.17% |
| 2022 Q3 | 30.77 Billion KRW | 6.13% |
| 2022 Q1 | 28.9 Billion KRW | -5.11% |
| 2021 Q1 | 13.29 Billion KRW | 5.19% |
| 2021 Q4 | 30.46 Billion KRW | -7.95% |
| 2021 Q2 | 32.87 Billion KRW | 147.29% |
| 2021 Q3 | 33.09 Billion KRW | 0.65% |
| 2021 FY | 30.46 Billion KRW | 141.01% |
| 2020 FY | 12.63 Billion KRW | 7.6% |
| 2020 Q1 | 11.77 Billion KRW | 0.26% |
| 2020 Q3 | 11.3 Billion KRW | -6.35% |
| 2020 Q4 | 12.63 Billion KRW | 11.77% |
| 2020 Q2 | 12.07 Billion KRW | 2.52% |
| 2019 Q4 | 11.74 Billion KRW | 3.65% |
| 2019 FY | 11.74 Billion KRW | 1.03% |
| 2019 Q3 | 11.33 Billion KRW | 4.85% |
| 2019 Q2 | 10.8 Billion KRW | -2.98% |
| 2019 Q1 | 11.14 Billion KRW | -4.18% |
| 2018 Q4 | 11.62 Billion KRW | 7.3% |
| 2018 Q2 | 10.45 Billion KRW | 9.45% |
| 2018 FY | 11.62 Billion KRW | 49.86% |
| 2018 Q1 | 9.55 Billion KRW | 23.14% |
| 2018 Q3 | 10.83 Billion KRW | 3.63% |
| 2017 Q1 | 8.01 Billion KRW | 8.92% |
| 2017 Q4 | 7.75 Billion KRW | 7.77% |
| 2017 FY | 7.75 Billion KRW | 5.44% |
| 2017 Q3 | 7.19 Billion KRW | -5.56% |
| 2017 Q2 | 7.62 Billion KRW | -4.88% |
| 2016 Q2 | 10.61 Billion KRW | -7.25% |
| 2016 Q4 | 7.35 Billion KRW | -3.64% |
| 2016 FY | 7.35 Billion KRW | -31.59% |
| 2016 Q3 | 7.63 Billion KRW | -28.07% |
| 2016 Q1 | 11.44 Billion KRW | 6.41% |
| 2015 Q2 | 10.03 Billion KRW | -40.45% |
| 2015 FY | 10.75 Billion KRW | -30.34% |
| 2015 Q4 | 10.75 Billion KRW | 1.87% |
| 2015 Q3 | 10.55 Billion KRW | 5.2% |
| 2015 Q1 | 16.85 Billion KRW | 9.15% |
| 2014 FY | 15.44 Billion KRW | -8.88% |
| 2014 Q3 | 18.86 Billion KRW | 5.36% |
| 2014 Q2 | 17.9 Billion KRW | 19.76% |
| 2014 Q1 | 14.94 Billion KRW | -11.8% |
| 2014 Q4 | 15.44 Billion KRW | -18.13% |
| 2013 Q3 | 32.3 Billion KRW | -0.15% |
| 2013 Q4 | 16.94 Billion KRW | -47.54% |
| 2013 Q2 | 32.35 Billion KRW | 0.26% |
| 2013 Q1 | 32.26 Billion KRW | -7.39% |
| 2013 FY | 16.94 Billion KRW | -51.36% |
| 2012 FY | 34.84 Billion KRW | 90.07% |
| 2012 Q4 | 34.84 Billion KRW | 0.0% |
| 2012 Q1 | 18.44 Billion KRW | 0.0% |
| 2011 Q3 | 13.8 Billion KRW | -39.86% |
| 2011 Q2 | 22.96 Billion KRW | 4.27% |
| 2011 Q1 | 22.01 Billion KRW | 16.69% |
| 2011 FY | 18.33 Billion KRW | -2.85% |
| 2010 Q1 | 10.39 Billion KRW | 7.4% |
| 2010 Q4 | 18.87 Billion KRW | 31.11% |
| 2010 FY | 18.87 Billion KRW | 94.94% |
| 2010 Q2 | 10.67 Billion KRW | 2.7% |
| 2010 Q3 | 14.39 Billion KRW | 34.8% |
| 2009 Q3 | 11.66 Billion KRW | 43.9% |
| 2009 Q2 | 8.1 Billion KRW | 3.14% |
| 2009 Q1 | 7.85 Billion KRW | -19.64% |
| 2009 FY | 9.68 Billion KRW | -1.01% |
| 2009 Q4 | 9.68 Billion KRW | -17.0% |
| 2008 Q1 | 35.12 Billion KRW | -2.95% |
| 2008 Q4 | 9.77 Billion KRW | -72.69% |
| 2008 FY | 9.77 Billion KRW | -72.98% |
| 2008 Q2 | 34.47 Billion KRW | -1.87% |
| 2008 Q3 | 35.8 Billion KRW | 3.86% |
| 2007 FY | 36.19 Billion KRW | 0.0% |
| 2007 Q4 | 36.19 Billion KRW | 2.85% |
| 2007 Q3 | 35.19 Billion KRW | 2.86% |
| 2007 Q2 | 34.21 Billion KRW | -0.24% |
| 2007 Q1 | 34.29 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ORIENT BIO Inc. | 11.89 Billion KRW | -58.044% |
| Green Cross Holdings Corporation | 1856.16 Billion KRW | 98.987% |
| Green Cross Holdings Corporation | 1103.45 Billion KRW | 98.297% |
| Green Cross Corporation | 1103.45 Billion KRW | 98.297% |
| GeneOne Life Science, Inc. | 39.51 Billion KRW | 52.442% |
| Celltrion, Inc. | 2791.73 Billion KRW | 99.327% |
| Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 99.698% |
| SK bioscience Co.,Ltd. | 148.58 Billion KRW | 87.351% |
| SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | 95.327% |
| Prestige BioPharma Limited | 196.21 Billion KRW | 90.422% |